In this video from Onc Live, Lymphoma Program Director, Dr. John P. Leonard, describes treatment options available to patients with indolent B-cell non-Hodgkin lymphoma.
Current treatment options for NHL include single-agent rituximab, R-CHOP, and bendamustine plus rituximab. Although early data shows potential for lenalidomide alone or in combination with rituximab.
The variety of options available for patients with indolent B-cell non-Hodgkin lymphoma is due to extensive clinical trial testing. If you are interested in learning more information about the clinical trials available at Weill Cornell Medicine you can visit the Joint Clinical Trials website.